Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Nietzsche who wrote (58667)	2/26/1999 12:07:00 PM
From: jopawa	Read Replies (1) \| Respond to of 119973

<Bid growing on BIGC> What's with that? Sitting at 1, low of the day.

To: Nietzsche who wrote (58667)	2/26/1999 12:08:00 PM
From: SpinCity1	Respond to of 119973

Garcia, Yes big bids on BIGC taking out the float of 700,000, yesterday 350,000 went out so the float is probably getting a whole lot smaller. IMGN- what is important about the release is that it is related to small-cell lung cancer which the medical field has had little to no sucess in developing treatments of in mice or men. SmithKline would not be interested if there wasn't some promise in this. NORWOOD, Mass., Feb. 3 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that it has executed an agreement with SmithKline Beecham Plc (SB), London, (London Stock Exchange: SB)/ SmithKline Beecham, Philadelphia (NYSE: SBH) to develop and commercialize ImmunoGen's lead tumor activated prodrug, huC242-DM1. Under terms of the agreement, in addition to royalties, ImmunoGen could receive up-front cash and milestone payments totaling more than $40 million. Additionally, at ImmunoGen's option, SB will purchase up to $5 million of ImmunoGen common stock over the next two years, subject to certain conditions.